Editorial Note: TMO at $527.05 RSI 64.7 has broken decisively out of the grinding consolidation flagged at the last two refreshes. At June 16, TMO was hugging SMA20 at $472.63, RSI 50.1, -26.61% off 52wk high. Since then: +3.21% 7D, +10.92% 30D, RSI has climbed to 64.7 (approaching overbought) and price is now +6.5% above SMA20 and essentially AT SMA200 ($526.58, +0.1%) for the first time across this series — the death cross remains technically intact but the gap has closed to nothing. From 52wk high has narrowed to -18.16% (vs -26.61% on 06/16). The biotech funding / pharma capex normalization thesis (thesis flag: intact) looks to be playing out — regime flips from "range-bound" language to "basing," consistent with a base resolving upward rather than more sideways grind.

2026-07-17 tape note: The SMA200 test has resolved slightly upward. TMO $532.48, RSI 62.3 (cooled modestly from 64.7), now +4.2% above SMA20 and +0.8% above SMA200 ($528.36) — clearing it for the first time in this series, though the margin is thin. 7D +1.03%, 30D +14.61% (accelerated), 3M +1.33%. -17.32% from 52wk high (marginal improvement). Regime "basing" continues. No new fundamentals re-researched.

2026-07-25 tape note: TMO has cleared overbought, crossing RSI 71 for the first time in this series. TMO $568.26, RSI 71 (up sharply from 62.3), now +7.8% above SMA20 ($527.20) and +7.5% above SMA200 ($528.84) — the SMA200 clearance has widened decisively from a thin +0.8% margin a week earlier, though the death cross remains technically intact. 7D +6.72%, 30D +15.45% (accelerated further), 3M +21.1% (up sharply from +1.33% as the window rolled past a prior low). -11.13% from 52wk high (narrowed materially from -17.32%). Regime reads "pullback" in the summary data despite the price strength — a classification quirk against a name that just broke to new relative highs, not a contradiction of the tape. Recent developments: per MarketBeat (2026-07-23), the move follows a strong second-quarter print and a raised full-year outlook, pointing to improving demand across TMO's end markets — consistent with the RSI 71 breakout this week. No new fundamentals re-researched beyond this news item.

2026-07-28 tape note: The breakout has extended, still overbought. TMO $576.41 (+1.4% vs $568.26), RSI 70.3 (essentially flat vs 71, still overbought) — +8.8% above SMA20 (extended from +7.8%) and +9% above SMA200 (extended from +7.5%), death cross still technically intact. 7D has improved to +10.12% (from +6.72%), 30D is roughly flat at +13.82% (from +15.45%), and 3M is roughly flat at +23.75% (from +21.1%). -10.49% from 52wk high — narrowed further from -11.13%. Regime now reads "uptrend," matching the price action rather than the "pullback" classification quirk flagged 07/25. No new fundamentals re-researched; RSI remains overbought — no chase warranted, watch for a pullback into SMA20 before adding. 2026-07-31 tape note: TMO $574.30 (-0.37% vs $576.41), RSI 68.8 (cooled from 70.3). 7D +1.06% (decelerated from +10.12%), 30D +11.88% (decelerated from +13.82%), 3M +22.52% (decelerated from +23.75%). From the 52-week high, the gap is -10.82% (essentially flat from -10.49%). Per the tape: trend "up", regime "pullback", no golden cross. No new fundamentals re-researched. Per the full-scan summaries (2026-07-31 close). 2026-08-08 tape note: TMO $594.00 (+3.43% vs $574.30), RSI 71.6 (warmed from 68.8). 7D +3.43% (accelerated from +1.06%), 30D +16.44% (accelerated from +11.88%), 3M +27.87% (accelerated from +22.52%). From the 52-week high, the gap is -10.27% (narrowed from -10.82%). Per the tape: trend "up", regime "breakout", death cross confirmed. No new fundamentals re-researched. Per the full-scan summaries (2026-08-07 close). 2026-08-14 tape note: TMO $588.29 (-0.96% vs $594.00), RSI 63.2 (cooled from 71.6). 7D -0.96% (turned negative from +3.43%), 30D +9.90% (moderated from +16.44%), 3M +34.34% (accelerated from +27.87%). From the 52-week high, the gap is -7.47% (narrowed from -10.27%). Per the tape: trend "up", regime "breakout", death cross confirmed. No new fundamentals re-researched. Per the full-scan summaries (2026-08-14 close).

Price Data

Key Changes vs 07/28

Research Log

Sources

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-31 close — *.
• News: latest (MarketBeat, 2026-07-23).
• Prior-cycle history: this file's dated update log (refreshed each full scan).